NMR quantification of TMAO
AssigneeLipoScience, Inc.
InventorsJames D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus, Stanley L. Hazen
Life of this patent
Estimating the term…
Abstract
A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM.
Claims19
A method of determining a measure of TMAO in in vitro biosamples, comprising:
- calibrating NMR measurements for trimethylamine-N-oxide (“TMAO”) by identifying a location of a pH-stable reference peak and using a defined linear relationship between the location of the pH-stable reference peak and a location of a pH-sensitive calibration peak;
- generating a proton NMR spectrum for an in vitro biosample;
- and
- electronically determining a level of TMAO in the in vitro biosample using a defined TMAO peak region having a single TMAO peak residing between about 3.2 and 3.4 ppm of the proton NMR spectrum, wherein the level of TMAO is in a range of 1 μM to 50 μM, and
- wherein the calibration peak is electronically identified in a defined calibration peak region in the proton NMR spectrum of the biosample.
One or more processors configured to evaluate in vitro biosamples, the processor configured to:
- calibrate NMR measurements for trimethylamine-N-oxide (“TMAO”) by identifying a location of a pH-stable reference peak and using a defined linear relationship between the location of the pH-stable reference peak and a location of a pH-sensitive calibration peak;
- generate a proton NMR spectrum for an in vitro biosample;
- and
- electronically determine NMR signal in at least one defined peak region that includes a TMAO peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample to determine a level of TMAO,
- wherein the calibration peak is electronically identified in a defined calibration peak region in the NMR spectrum of the biosample, and wherein the level of TMAO is in a range of 1 μM to 50 μM.
A method of monitoring patients for therapeutic treatment, comprising:
- electronically determining a level of trimethylamine-N-oxide (“TMAO”) in an in vitro biosample from a subject using a defined TMAO peak region having a single TMAO peak residing between about 3.2 and 3.4 ppm of a proton NMR spectrum;
- and
- administering a prebiotic, probiotic, or drug to a patient for treatment of kidney transplant rejection or fish odor syndrome based on the level of TMAO in the biosample.
Dependencies are inferred from the claim text.